F500 Pharma & Biotech · Pharmaceuticals · No confirmed finding (unverified, not clean)
AbbVie
Headline
Nothing confirmed
Nothing company-specific confirmed this pass.
Not independently verified. Verification status: Unverified - heuristic first draft. Publish state: draft unverified.
What this pass recorded. Nothing company-specific confirmed this pass. AbbVie's patient support programmes for high-cost specialty drugs collect diagnosis, insurance and financial information from patients who often have no alternative route to affording treatment - the same structural exposure documented concretely in the Johnson & Johnson and Cencora rows. The Cencora incident specifically caught data from at least 27 pharmaceutical and biotech companies' patient support programmes, so a manufacturer with no breach of its own may still have had its patients exposed through the distributor. Recommend checking AbbVie against the Cencora notification list.
- Severity
- Evidence tierUnassigned
- Claims confirmed
- Last verified2026-08-04
Primary source. None recorded — Unverified - heuristic first draft.
Terms
Arbitration
Not independently confirmed this pass — standard binding arbitration + class action waiver expected.
Data sharing
Not independently confirmed this pass with a company-specific consumer data lawsuit beyond the shared industry findings below. SHARED FINDING ACROSS MANY PHARMA COMPANIES: (1) A 2024 breach at CENCORA (a major pharmaceutical distributor, documented separately in the Healthcare Providers tab of this tracker) exposed patient information — names, addresses, birthdates, health diagnoses, and prescriptions — for patients receiving medications marketed by this company, among more than a dozen other manufacturers (Bayer, Genentech, AbbVie, Novartis, Regeneron, GSK, and others) whose distribution flowed through Cencora. (2) A SEPARATE 2026 putative class action, Nash v. Tempus AI, Inc., No. 1:26-cv-01688 (N.D. Ill., filed Feb. 13, 2026; Tempus's Q2 2026 10-Q describes a Feb. 12, 2026 filing with three companion cases), under the Illinois Genetic Information Privacy Act, alleges Tempus AI obtained Ambry Genetics customers' genetic data through its 2025 acquisition of Ambry and disclosed it to third parties without written consent; the complaint quotes Tempus's own statement listing AbbVie among more than 70 pharma/biotech companies that signed data agreements with Tempus in 2025, and quotes Tempus's CFO saying 'We have a large data business.' These are allegations against Tempus; AbbVie is not a defendant (status not re-verified as of Oct 2026).
Fees and billing
Not itemized this pass.
Contacts
Privacy contact. Not recorded.
Legal notice. Not verified this pass. If publicly traded: SEC Form 10-K cover page gives the official corporate address; the Secretary of State business-entity search in the state of incorporation gives the registered agent, which must accept service. If private: the state registered agent is usually the only reliable route.
Mailing address. Not recorded.
Evidence
No claims have been itemized for this row yet.
No sources are on file for this row yet.
Source vault
Link status: Candidate - not yet fetched
| Document | Last fetch | |
|---|---|---|
| Privacy policy See AbbVie's own published privacy policy | Not fetched yet | NOT CONFIRMED |
| Terms of service See AbbVie's own published terms of service | Not fetched yet | NOT CONFIRMED |
| Website No URL recorded | Not fetched yet | — |
| Primary source No URL recorded Verification: Unverified - heuristic first draft | Not fetched yet | — |
Enforcement
No enforcement actions are linked to this row.
State statute
No HQ state on file, so no state statute applies by headquarters.